Partner Insights spoke to Maxwell Wu, Co-founder and CEO at Fulcrum Lending based in New York City about his firm’s unique ...

Fulcrum Therapeutics has a 1 year low of $2.78 and a 1 year high of $10.13. Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last released its quarterly earnings results on Tuesday, February ...

Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027.

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company ...

Explore Fulcrum Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for FULC. Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending ...